Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;47(3):100-101.
doi: 10.18773/austprescr.2024.028.

Recombinant respiratory syncytial virus (RSV) vaccines for older adults, and pregnant women to prevent disease in their infant

No authors listed
Review

Recombinant respiratory syncytial virus (RSV) vaccines for older adults, and pregnant women to prevent disease in their infant

No authors listed. Aust Prescr. 2024 Jun.
No abstract available

Keywords: Abrysvo; Arexvy; RSV; respiratory syncytial virus; vaccines.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Therapeutic Goods Administration. Australian Production Information - AREXVY recombinant respiratory syncytial virus pre-fusion F protein vaccine. Department of Health and Aged Care; 2024. https://www.tga.gov.au/resources/artg/400657 [cited 2024 May 28]
    1. Therapeutic Goods Administration. Australian Product Information - ABRYSVO recombinant respiratory syncytial virus pre-fusion F protein bivalent vaccine. Department of Health and Aged Care; 2024. https://www.tga.gov.au/resources/artg/406624 [cited 2024 May 28]
    1. Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al. RENOIR Clinical Trial Group . Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med 2023;388:1465-77. 10.1056/NEJMoa2213836 - DOI - PubMed
    1. Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et al. AReSVi-006 Study Group . Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med 2023;388:595-608. 10.1056/NEJMoa2209604 - DOI - PubMed
    1. Australian Technical Advisory Group on Immunisation. ATAGI statement on the clinical use of Arexvy (RSV PRE-F3) vaccine for RSV. Department of Health and Aged Care; 2024. https://www.health.gov.au/resources/publications/atagi-statement-on-the-... [cited 2024 May 6]

LinkOut - more resources